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The efficacy of energy-restricted diets in achieving preoperative weight loss for 
bariatric patients:  A systematic review. 
Abstract  
In bariatric practice, a preoperative weight loss of at least 5% is recommended. 
However, the hypocaloric diets prescribed vary and no consensus exists. This study 
examined the efficacy of preoperative diets in achieving 5% weight loss. From a 
systematic literature search, eight randomised controlled trials (n=862) were 
identified. Half of the trials used a “Very-low-calorie diet” whilst the rest employed a 
“Low-calorie diet”. Only five diets achieved >5% weight loss over varying durations 
and energy intake.  By inference, compliance with a 700-1050kcal (2929-4393kJ) 
diet, consisting of moderate carbohydrate, high protein and low/moderate fat, for three 
weeks is likely to achieve 5% weight loss. A low CHO diet (<20g/day) may achieve 
this target within a shorter duration. Additional research is required to validate these 
conclusions.  
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Introduction  
Obesity is a major global health issue both in terms of its increasing trajectory and as 
one of the leading causes of morbidity and mortality (1–5). Presently, bariatric 
surgery is accepted as the most effective treatment for the management of morbid 
obesity (6–8). It is also termed “metabolic surgery” since the weight loss mechanisms 
extend beyond food restriction and nutrient malabsorption by altering physiological 
and metabolic processes to induce larger amounts of sustainable weight loss (9,10).  
However, bariatric surgery is not entirely risk-free and carries potential complications 
ranging from 5 to 20% (11).  Consequently, bariatric guidelines (12–15) support an 
intentional preoperative weight loss to reduce the liver volume (13,14) and risk of 
perioperative complications (12,13,15). It is particularly challenging for surgeons to 
elevate the left lobe of a large or fatty liver (16,17), especially during laparoscopic 
Roux-en-y gastric bypass surgery (RYGB), thereby, increasing the risk of liver injury 
and intraoperative bleeding (18). Furthermore, an enlarged liver contributes to an 
estimated 50% of minimally invasive laparoscopic RYGB procedures transitioning to 
an open procedure (19,20) making the surgery more invasive and increasing the risk 
of wound infections, length of hospital stay and recovery time (13). Nevertheless, 
with advances in technique and technology, when bariatric surgeons encounter a large 
liver, they may choose to either postpone the surgery or execute a simpler procedure 
of second choice such as the sleeve gastrectomy. 
A total weight loss (%TWL) of at least 5% (21–23) has been shown to achieve the 
general liver volume reduction target of approximately 10% (18,24).  Furthermore, 
losing at least 5%TWL has also been recommended for the treatment of non-alcoholic 
fatty liver disease (25). This is compatible with the general consensus that, regardless 
of a scheduled bariatric surgery, a modest weight loss, defined as 5-10 %TWL, has 
benefits on existing comorbidities (25,26) such as ameliorating hyperglycaemia or 
cardiovascular risk factors which are associated with increased perioperative risks 
(27,28). 
The most recent bariatric guidelines (14,15) and literature (24,29–33) are in favour of 
energy-restricted diets to achieve rapid preoperative weight reduction. However, there 
is significant heterogeneity in the type of energy-restricted dietary regimes being 
prescribed (34). For example, an observational study, involving one-third of the 
bariatric centres in the United Kingdom found extensive variability in the type of 
energy-restricted diets prescribed preoperatively (35).  
Given this lack of consensus amongst bariatric professions, there is a need to 
systematically review the highest level of evidence to determine the magnitude, 
macronutrient composition and duration of energy-restricted diets that may optimally 
achieve a preoperative weight loss of at least 5%.  
 
 
 
 
 
 
 
 
 
 
 
 
Methods  
The Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) 
checklist (36) was used as a basis for this review.  
Eligibility criteria 
The PICO (population, intervention, comparator, outcomes) formula (37,38) was 
adopted to develop the clinical question and eligibility criteria as follows: 
Review question Can preoperative energy-restricted diets for bariatric patients 
incur significant weight loss? 
Population Human subjects of any age with any degree of obesity who are 
scheduled for bariatric surgery. 
Intervention English-language randomised controlled trials exploring the 
efficacy of preoperative energy-restricted diets on weight loss. 
Trials published from 2013 onwards.  
Comparator Comparison of energy-restricted diets, standard diets, other 
weight loss strategies, macronutrient composition, varying 
durations, no dietary intervention or placebo. 
Outcomes Primary outcomes: Body weight, Body Mass Index (BMI), % 
excess weight loss, % total body weight lost. 
Secondary outcomes:  Any positive or adverse health outcomes 
and observed changes in: 
 Biochemical and clinical variables. 
 Liver volume. 
 Visceral fat. 
 Length of hospital stay. 
 Duration of surgery. 
 Surgery-related complications. 
 Mortality. 
 
Setting Hospital wards, bariatric centres, outpatient settings, home. No 
restrictions. 
 
Information sources 
Literature specific to the review question was identified by searching the following 
electronic databases from 2013 to June 2017: PubMed, CINAHL, Cochrane Library, 
Web of Science and Science Direct.   
In addition to performing citation searches on key articles, hand searching the 
bibliographies of relevant retrieved articles and contacting authors for missing details,  
the search was supplemented with the following alternative sources: ClinicalTrials 
(http://clinicaltrials.gov), Clinical UK trials (https://www.ukctg.nihr.ac.uk/), 
PROSPERO (https://www.crd.york.ac.uk/PROSPERO/) and National Institute for 
Health and Care Excellence’s evidence search website 
(https://www.evidence.nhs.uk/). 
Search strategy 
The search strategy incorporated truncation and speech marks for phrases to capture 
variation in terminology, where possible. Boolean logic operators was utilised for the 
electronic search engines. The following key words and/or Medical Index Subject 
Headings and related synonyms were used: (“Clinical efficacy” OR “treatment 
outcome*” OR “body weight” OR “blood glucose” OR “glycosylated hemoglobin” 
OR “glycosylated haemoglobin” OR “blood pressure” OR Liver OR Fat OR Adipos* 
OR “Inter-abdominal”) AND (Preoperative OR “Before surgery” OR “Pre-surgery”) 
AND (“Weight loss diet*” OR “Diet reducing” OR  “Weight reduction diet*” OR 
“Very Low Calorie Diet*” OR “Caloric restriction” OR “Low Calorie Diet*” OR 
“Very Low Energy Diet*” OR “Low Energy Diet*” OR VLCD OR LCD OR “Liquid 
Diet*” OR “Meal replacement*”) AND (“Bariatric surgery” OR “Weight Loss 
Surgery” OR “Metabolic surgery” OR “Sleeve gastrectomy” OR “Gastric bypass” OR 
“Laparoscopic Adjustable Gastric Banding”). 
Data management 
The literature search results were uploaded to EndNote (39) to facilitate the 
management of identified records and allow easy identification of duplicate studies.  
Selection process 
In the first stage of study selection, one reviewer independently screened the titles and 
abstracts as per predetermined eligibility criteria. In the second stage, full articles 
were retrieved if adequate information was unavailable from the abstracts. Any 
uncertainties were clarified and discussed with the supervisor in-charge (OF) of this 
review.  
Data collection process and data items 
One reviewer extracted data independently from eligible articles using a standardized 
template as per Centre for Reviews and Dissemination Guidelines (CRDG) (40).  
Assessing bias and quality of selected studies 
The methodological quality of the trials was appraised using the Downs and Blacks 
Checklist (41). Any lack of clarity was discussed with OF. For the purpose of clarity, 
the last question on power was modified to two options whereby one point was 
assigned if the trial had conducted a power calculation and zero points if not. 
Therefore, this simplified version has a maximum score of 28. Additionally, scores 
less than 14 were graded “poor”, 14 to 18 as “fair”, 19-23 as “good” and 24-28 as 
“excellent” quality. This method has been adopted by a previous study (42). 
Data synthesis 
Relevant details are presented as a systematic narrative synthesis in the following 
order to highlight key findings:  trials characteristics, details of energy-restricted diets, 
weight loss and secondary outcomes.  A meta-analysis could not be conducted due to 
the heterogeneity of the data. 
Confidence in cumulative estimate 
The strength of the evidence was determined using the CRDG’s hierarchy of evidence 
level (40). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results  
Selected RCTs 
The literature search results are summarised in Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The Preferred Reporting Items for Systematic Reviews and Meta-analysis 
(PRISMA) flow diagram for study inclusion. 
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Characteristics of identified RCTs 
The eight trials (total n =862 participants) consisted of, on average, 80% females with 
age and BMI ranging from 36 to 47 years and 37.4 to 59.0 kg/m
2 
respectively. Two of 
the selected RCTs were abstracts presented at conferences (43,44) and one was a brief 
report (45). Five of the trials were conducted in Europe (43–47), two in North 
America (48,49) and one in South America (50). Five trials reported attrition rates 
ranging from 6.7 to 27%.  The study settings included hospitals (43–45), specialised 
clinics (47–50)  and a university (46). The characteristics of the RCTs are summarised 
in Table 1. 
Diet interventions 
Fifty percent of the RCTs used Very Low Calorie Diets (VLCD) consisting of 647 to 
800kcal (2707-3347kJ) per day (44,45,47,50) (Table 2) and the other half adopted 
Low Calorie Diets (LCD) with energy content ranging from 1030 to 1600kcal (4310-
6694kJ) per day (43,46,48,49) (Table 3).  The diet duration ranged from 10 days to 
six months with two weeks being the most common duration (N=6 diets). (43,45,50).  
The majority of the RCTs compared groups that were both energy-restricted and 16 
distinct types of diets were identified (Table 2 & 3). It is unclear whether energy 
intake was restricted for the control group in one of the trials (44). 
Only one RCT used an energy-restricted diet based solely on liquid food products 
(50). Three trials did not indicate the diet consistency (43–45)  and the rest used a diet 
which incorporated both liquid and solid food products.  
Weight loss outcomes 
As outlined in Table 4, five diets achieved at least 5%TWL (44,46,48,49) and 11 did 
not achieve this target (Table 4). Two VLCD diets just failed to achieve the 5% 
weight loss target (4.8%) (47). 
Secondary outcomes 
There is a high degree of heterogeneity in the secondary outcomes described and 
corresponding measurement methods as well as reporting units (Table 5).   
Two RCTs reported reductions in liver size after 3-5%TWL (43,44). Only one trial 
reported significant visceral fat changes after 3.5%TWL (50). The same trial found an 
inverse relationship between surgery time and visceral fat in the liquid VLCD group 
(P=0.0014). Another trial observed that the duration of surgery for the group 
following a VLCD diet was 10 minutes shorter than the control group that was on a 
“normal” diet (P=0.16) (44).  
Four RCTs observed improvements in biochemical risk factors following energy-
restriction and varying degrees of success in weight loss (45,46,49,50). One trial 
reported a positive shift in clinical risk factors which included a decrease in blood 
pressure after a LCD for seven weeks (46). There was no significant difference 
between groups for perioperative complications (44,47,50).  
 
 
 
 
 
 
 
 
 
Discussion  
A striking feature about the literature in this area is an increase in the number of 
publications of RCTs since 2014, probably due to the growing recognition that 
preoperative weight loss may optimise some perioperative outcomes (30,32,33,51). 
The %TWL was not reported by three RCTs (43,44,49) and the values were estimated 
via inference from reported data (Table 4). Overall, the five diets (44,46,48,49) that 
successfully achieved at least 5%TWL exhibited considerable heterogeneity in terms 
of energy intake and duration. 
Regarding energy intake, the four VLCD trials (35,44,47,50) prescribed 647-800 kcal 
(2707-3347 kJ) which is in line with the accepted definition of a diet providing less 
than 800 kcal per day (3347 kJ) (8,52,53). The remaining four LCD trials 
(43,46,48,49) prescribed 1030-1600 kcal (4310-6694 kJ) as per its standard definition 
of a diet restricted to 1200-1600 kcal per day (5021-6694 kJ) (54). However, 
compliance with the prescribed intake of energy is debatable for the majority of the 
trials. Three did not report a method for assessing compliance with the prescribed diet 
(44,48,49) and four relied on self-reported methods (35,43,46,47) which are 
notoriously prone to under-reporting of “socially undesired” food and beverages by 
obese individuals (55,56). In order to overcome this, future trials should attempt to 
supplement the self-reported measures with weight loss biomarkers (57) or conduct 
the dietary intervention in a controlled environment with convert supervision. This 
may also provide insight into the acceptability and willingness of patients to adhere to 
energy-restricted diets. 
In terms of diet duration, all the diets of a two weeks duration (35,43,50) and some 
diets of a longer duration of 12-24 weeks (48,49) failed to achieve 5%TWL. 
Interestingly, other diets with the same duration of 12-24 weeks (48,49) successfully 
achieved 5%TWL.  However, the weight loss achieved by the longer-term diets was 
comparable to the short duration diets of 4-11 weeks (44,46). This could be attributed 
to the well-recognised and expected slowing down of weight loss after an active 
weight reduction phase (8). Hence, it is realistic to assume that 5%TWL can be 
achieved in a shorter duration.  
In fact, two diets (47) achieved 4.8%TWL in less than two weeks. These were the 
only diets that prescribed a very low carbohydrate, high protein and low/moderate fat 
diet that is defined as providing less than 20g of carbohydrate per day (58,59) and at 
least 20% of protein (60) and less than 35% of fat (61) (low fat) from total energy 
intake. The very low carbohydrate diet could have encouraged mild ketosis and 
suppressed hunger levels which aided the rapid weight loss observed (53,62). 
However, apart from the fact that a low carbohydrate diet is a topic of controversy 
(63), it is not ideal for a patient to be in a catabolic state during surgery as it may 
increase the risk of poor recovery postoperatively and even morbidity (18,33,64). 
Nevertheless, the catabolic extent of a short-term, low carbohydrate VLCD diet is 
unclear and requires further robust research as it may be an option to achieve a larger 
preoperative weight loss within a shorter span of time. 
Six diets did not report the macronutrient composition (44,48,49) and the remaining 
interventions (n=8) (35,43,45–47) prescribed a moderate carbohydrate (>20g of 
carbohydrate per day but <50% of total energy intake from carbohydrates) (65) ,  high 
protein (>20% of energy from protein) (60),  and low/moderate fat diet (<35% of 
energy from dietary fat) (61). By inference, these diet prescriptions resulted in longer 
duration of at least three weeks to achieve 5%TWL (Table 4). Therefore, this finding 
suggests that the macronutrient mix of the diet plays a role in determining the duration 
taken to achieve 5%TWL.  
This review is unable to determine whether an energy restricted diet consisting of 
liquid foods is more superior in promoting weight loss as only one diet explored this 
and failed to achieve 5%TWL at two weeks (37).  Nevertheless, despite not achieving 
the target weight loss, the trial demonstrated that the liquid VLCD group achieved 
significantly more reduction in visceral fat thickness (20.6%) compared to the VLCD 
group that incorporated both solid and liquid foods (0.28%). This is encouraging as it 
may minimise the risk of converting a laparoscopic procedure to an open bariatric 
surgery since the reduction in visceral adiposity allows more space for 
pneumoperitoneum, which is a practice required during laparoscopic surgery (23). 
Further research is merited to confirm, or otherwise, whether energy-restricted diets 
incorporating liquid food products induce greater visceral fat loss and improve 
subsequent surgery duration or complication rates. 
Similarly, two trials observed that just 2 -3.5%TWL optimises blood glucose levels 
and lipid profile (49,50) that could consecutively minimise perioperative risks 
(27,28). Another trial demonstrated that less than 5%TWL results in liver shrinkage 
(43) that reduces the risk associated with the laparoscopic procedure (16–18). Hence, 
it may be worthwhile to encourage preoperative weight loss in obese individuals 
regardless of the degree of weight loss achieved. 
Quality of evidence 
RCTs are considered to be the highest evidence level according to the CRDG’s 
hierarchy of evidence level (40).  However, the majority of studies were assessed as 
weak methodological quality (Table 1). The abstracts used in this review represent 
grey literature and were included to minimise location bias (66) but inevitably they 
were limited in detail. Although the authors were contacted (43,44), no further 
information was available.  
The results from this review are mainly applicable to Western adult females who are 
in the obesity class three category and motivated to lose weight. Caution should be 
used when translating these results to other populations such as Asians who have a 
different body composition (67). It is also uncertain how generalizable these findings 
are to adults older than 60 years old.   
Precautions should be taken in individuals with disease status that may be affected by 
energy-restriction – for instance, porphyria, renal and/or liver failure, diabetes being 
treated with sulphonylureas (68). This is important information for bariatric 
guidelines to consider including, in future publications. 
Quality of the systematic review 
The limitations associated with this review are acknowledged.  Firstly, the findings 
should be interpreted with caution as it is based on a relatively small number of 
“poor” to “fair” quality RCTs. The reviewer was not blinded to the literature sources 
and authors of the trials and there is also language bias as studies with negative 
outcomes tend to being published mostly in non-English journals (36). It was also 
beyond the scope of this research to thoroughly examine the safety and impact of 
preoperative weight loss on nutritional status prior to bariatric surgery.  
Notwithstanding the above limitations, this is the first systematic review that 
exclusively examined RCTs that investigated the effects of energy-restricted diets on 
preoperative weight loss. Its validation was strengthened by using the PRISMA for 
protocol guidance, PICO formula to guide the review question, standardised 
extraction forms and supplementing the comprehensive electronic search with grey 
literature; so as to minimise location bias (69). Furthermore, all the trials identified 
were retrieved despite some of them being unavailable from the primary database.  
Implications for future research 
The uncertainty and bias in the existing evidence base calls for improvement in the 
execution and monitoring of dietary interventions as well as in the measurement and 
reporting of weight loss outcomes. Future studies in this area should: 
 Express mean weight loss in kilograms and %TWL as a minimum.  
 Specify the energy and macronutrient composition of prescribed and self-
reported diet. 
 Highlight any concurrent interventions. 
 List any adverse effects associated with the diet. 
 Specify the weight and height measuring instruments used and precautions 
taken to ensure measurement accuracy i.e. calibration.  
 Consider objective method to monitor dietary intake (e.g. controlled 
environment). 
 Conduct a rigorous RCT that is double-blinded with proper allocation 
concealment and an intention-to-treat analysis. 
 Report percentage reduction in liver volume and indicate measurement 
method. 
Conclusion  
In conclusion, this systematic review has highlighted that intentional preoperative 
weight loss should be encouraged as it aids in ameliorating some risk factors that may 
potentially contribute to perioperative complications. Importantly, energy-restricted 
diets serve as a feasible and non-invasive method to achieve preoperative weight loss. 
The findings are also of clinical significance to medical teams overseeing surgical 
emergencies in obese individuals. 
It is difficult to make any definitive evidence-based conclusions based on the limited 
number of trials as well as missing information. However, based on the current 
evidence, it is hypothesized that a diet consisting of 700 to 1050 kcal (2929-4393kJ) 
with moderate carbohydrate, high protein and low/moderate fat may induce 5%TWL 
over three weeks
. 
Although a low carbohydrate (<20g/day) diet may achieve this 
target within a shorter duration of less than two weeks, its safety for bariatric 
candidates remains ambiguous. Further research through well-designed RCTs is 
needed to address these gaps in knowledge and to confirm the validity of the above 
conclusion. 
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Table 1 Characteristics of included randomised controlled trials. 
BMI Body mass index, CG Control group, EC Exclusion criteria, IC Inclusion criteria, IG Intervention group, LCD Low calorie diet, NA Not available, Age and BMI presented as mean (SD) or 
†† median (range) or #unclear, § Preoperative phase, †As reported in paper, ^ Overall score based on Downs and Black’s checklist, ¶ Conference abstracts with limited information.  
Author,  
year,  
country 
% Female 
 
Age (Years) Baseline BMI 
(kg/m2) 
Subjects 
enrolled 
(n) 
Subjects 
analysed 
(n) 
Attrition 
rates (%) 
Study 
quality^ 
Inclusion/exclusion criteria specified 
Chakravartty¶   
2014 
UK (44) 
95 IG:43.5 (NA)†† 
CG:38.5 (NA)†† 
IG:53.4 (NA)†† 
CG:52.75 (NA)†† 
IG:10 
CG:10 
IG:NA 
CG:NA 
NA Poor¶ NA¶ 
Heinberg  
2014 
USA (49) 
71 IG1:47.79±47.79† 
IG2:46.95±10.86 
 
IG1:49.45±10.63 
IG2:49.75±8.61 
 
IG1:33 
IG2:40 
 
IG1:28 
IG2:38 
IG1: 15% 
IG2: 5 %  
Total:9.6% 
 
Poor IC: ≥18y, BMI ≥40/ ≥35 kg/m2 with medical comorbidities, fluent 
in English. EC: Nil 
Schütz¶ 
2014 
Germany (43) 
67 IG1:47.2 (NA)# 
IG2:46.3 (NA)# 
 
IG1:47.5 (NA)# 
IG2:47.5 (NA)# 
IG1:34 
IG2:36 
IG1:NA 
IG2:NA 
 
NA Poor¶ NA¶ 
Faria 
2015 
Brazil (50) 
81.7 IG1: 37.14±10.29 
IG2: 36.43±10.01 
IG1:42.40±4.83 
IG2:39.65±3.54 
IG1: 71 
IG2: 71 
IG1:57 
IG2:47 
IG1: 19.7% 
IG2:33.8% 
Total:27% 
Fair IC: Patients preparing for Roux-en-y gastric bypass surgery. EC: 
Nil 
Kalarchian  
2016 
USA (31) 
90.2 IG1: 43.9±10.3 
IG2: 45.9±11.6 
 
IG1: 47.5±6.4 
IG2: 47.4±6.2 
 
 
 
IG1:121 
IG2:119 
IG1:103 
IG2:81 
 
IG1:14.9% § 
IG2:31.9% § 
Total:23% § 
Fair IC:≥18y. EC: Intellectual disability, genetic obesity syndrome; 
weight loss 6 months prior, uncontrolled psychiatric issues, 
pregnant/ lactating, medication affecting weight, previous bariatric 
surgery, condition requiring a special preoperative care, BMI≥70 
kg/m2 requiring LCD, conflicting research involvement. 
Nielsen 
2016 
Denmark (46) 
73 IG1&2: 38·8 ±10·4 IG1&2: 46·0±4·4 IG1:30 
IG2:15 
IG1:30 
IG2:15 
Total:6.7% Fair IC: 18–65y, BMI ≥ 40/ ≥ 35 kg/m2 with obstructive sleep 
apnoea/hypertension. EC: Diabetes mellitus, thyroid dysfunction, 
hypothalamic/genetic aetiology of obesity, diverticulitis, 
arrhythmias, renal dysfunction, elevated liver enzymes, lactose 
intolerance, porphyria/ phenylketonuria, gout, lactating, use of 
monoamine oxidase inhibitors or non-potassium-sparing diuretics, 
inability to comply with LCD. 
Schouten  
2016  
Netherlands 
(47) 
78.8 IG1:40.2 (NA)# 
IG2:41.7 (NA)# 
IG1:42.8 (NA)# 
IG2:43.1 (NA)# 
IG1:105 
IG2:107 
 
IG1:105 
IG2:107 
 
NA Fair IC: BMI >40/>35 kg/m2 with at least two obesity-related 
comorbidities. EC: Untreated psychiatric disorders, 
cardiopulmonary disease, previous bariatric and/or gastric 
surgery,<18 or >60 years. 
Baldry  
2017 
UK (45) 
81.5 IG1:47 (40)†† 
IG2:42(35)†† 
IG1:51.1(25.4)†† 
IG2:50.1(21.4)††  
IG1:30 
IG2:30 
IG1:26 
IG2:28 
 
IG1: 13% 
IG2: 7% 
Total: 10% 
Fair IC: BMI >40 kg/m2. EC: <18, 2o NAFLD; diabetes treated by 
medication other than biguanides, excess alcohol intake, 
pregnancy, inability to comply with energy restriction. 
Table 2 Summary of Very Low Calorie Diet (VLCD) interventions. 
Author, year Duration 
(weeks) 
Prescribed  & 
self-reported  
energy intake 
(kcal) 
Diet details including diet texture (liquid/solid 
foods or mixed foods)  
Macronutrient 
composition 
Concurrent 
interventions 
Compliance  
data 
Reported side effects 
Chakravarrty  
2014 
(43) 
 
4  IG:  
800† 
NA†† 
CG:  
NA† & †† 
IG: VLCD, unknown consistency: no details. 
CG: Regular diet, mixed: no details. 
IG & CG: NA IG & CG: NA NA NA 
Faria  
2015 
(50) 
2  IG1:  
734-786† 
862-1054†† 
IG2: 
731-777†  
716-924†† 
 
IG1: VLCD, liquid: yogurt, soup, skim milk, 
coconut water 20g whey protein  
IG2: VLCD, mixed, regular diet, 10g whey 
protein. Both:1 vitamin and mineral supplement, 
detailed menus 
IG1&2: 70g 
CHO, 76g Pro, 
19g Fat † 
IG1&2: Dietitian X3 
visits 
24-hr dietary 
recall & 
Ketonuria 
detection 
(urinalysis) 
 
IG1: Week 0 vs. 7 & Week 0 vs. 14: 
No significant difference in degree of 
hunger. 
IG2: Week 0 vs. 7 & Week 0 vs. 14: 
Significant decrease in degree of 
hunger. 
Week 7 & 14: IG1 had significantly 
higher degree of hunger than 1G2 
(P<0.05) 
Intolerance (n=2) ?Group 
Schouten 
2016 
(47) 
10 days IG1: 
650† 
NA†† 
IG2: 
647-657†  
NA†† 
 
IG1: VLCD, mixed, Promided protein sachets: 1 
breakfast sachet, 1 lunch sachet with veg, 
fish/meat with veg, 1snack sachet.  
IG2: VLCD, mixed, dairy product, meat with 
veg, fish with veg & salad. Both: >1.5L of clear 
fluids ,3 multivitamin tablets 
IG1:12g CHO, 
101g Pro, 16g 
Fat† 
IG2: 20g CHO, 
81-86g Pro, 21-
25g Fat† 
IG1&2:NA Daily diet 
book. 
Mean scores 
IG1: Nausea: 3/10, Tolerance: 7/10, 
Hunger: 6/10. IG2: Nausea: 
3/10,Tolerance:8/10, Hunger:5/10 
Baldry  
2017 
(45) 
2  IG1: 
800† 
715 (558) †† 
IG2: 
800† 
715 (275) †† 
IG1: VLCD, unknown consistency, standard 
prebariatric diet 
IG2: VLCD, unknown consistency: Lighterlife 
MR diet 
 
 
IG1:93g CHO, 
54g Pro, 15g 
Fat†† 
IG2: 68g CHO, 
66g Pro, 20g 
Fat†† 
IG1&2:NA Self-reported 
evaluation 
 
Always feeling hungry IG1: 19%, IG2: 
15% 
CG Control group, CHO Carbohydrate, IG Intervention group, MR Meal replacement, NA Not available, Pro Protein, VLCD Very Low Calorie Diet 
† Prescribed amount 
†† Self-reported amount 
 
 
 
 
Table 3 Summary of Low Calorie Diet (LCD) interventions. 
Author, 
year 
Duration 
(weeks) 
Prescribed  & 
self-reported  
energy intake 
(kcal) 
Diet details including diet texture (liquid/solid 
foods or mixed foods) 
Macronutrient 
composition 
Concurrent 
interventions 
Compliance  
data 
Reported side effects 
Heinberg 
2014 
(48) 
12 IG1: 
1300-1600† 
NA†† 
IG2: No caloric 
goal 
IG1: LCD, mixed: portion-controlled low-glycemic 
Nutrisystem 3 meals, 1-2 snacks, fruits & 
vegetable, low-fat diary. 
IG2: No specific caloric goal, mixed: 1 protein 
liquid MR/day,3 meals/day, reduce fats and salt, 
1.8L calorie-free fluids 
IG1&2: NA IG1: 24 hours support 
 
IG1&2: Exercise 
X5/week, dietitian X3 
visits 
NA  IG1:Intolerance but no details 
IG2: NA  
Schutz  
2014 
(43) 
 
2  IG1: 
NA† 
753-1049†† 
IG2: 
NA† 
752-992†† 
 
IG1: LCD, unknown consistency: “high protein, 
low carbohydrate” product.  
IG2: LCD, unknown consistency, “high 
carbohydrate” product 
Both:200g vegetables daily 
 
IG1:80g CHO, 
75g Pro, 28g 
Fat† 
IG2: 111gCHO, 
58g Pro, 19g 
Fat† 
IG1&2: NA Nutrition 
diary 
NA 
Kalarchian 
2016 
(31) 
24 IG1: 
1200-1400† 
NA†† 
IG2: 
NA † 
NA†† 
 
IG1: LCD, mixed, “behavioural intervention”, 
balanced diet consistent with bariatric nutritional 
guidelines. 
IG2: “Usual care”, mixed, physician-supervised 
diet program 
IG1 & IG2:NA IG1: Exercise 
program & behaviour 
change technique 
expert  
IG2: Physician 
supervised activity 
program 
NA NA 
Nielsen 
2016 
(46) 
 
7 vs. 11 
weeks 
IG1&2: 
1030† 
NA†† 
(7 weeks vs. 11 
weeks) 
IG1&IG2: LCD, mixed, 4 Cambridge liquid 
meals,1L skim milk, 295g vegetables, 100g low-fat 
yoghurt (7 weeks vs. 11 weeks) 
 
IG1&2:122g 
CHO, 100g Pro, 
14g Fat† 
IG1&IG2: Weekly 
dietitian visits 
Five-point 
scale self-
evaluation. 
 
 
Headache (57%), fatigue (50%), 
constipation (43%), dizziness (33%) 
and upper respiratory infections 
(30%) 
Others: cold intolerance, hunger, 
abdominal pain, irritability, dry skin, 
diarrhoea, flatulence, bad breath 
 
CG Control group, CHO Carbohydrate, IG Intervention group, LCD Low Calorie Diet, MR Meal replacement, NA Not available, Pro Protein, † Prescribed amount, †† Self-reported amount 
 
 
 
 
Table 4 Weight loss outcomes. 
Author, 
year 
Total weight loss 
(kg) 
Total weight loss (%) Excess weight loss
 (%) ^ Change in BMI 
(kg/m2) 
Instrument to 
measure height 
Instrument to 
measure weight 
Precautions taken 
when measuring 
Chakravartty 
2014 
(43) 
IG:-6.5±2.0 
CG: -0.3±1.6 
P<0.001 
IG: >5¥ 
CG: <2¥ 
IG&CG:NA NA NA NA NA 
Heinberg 
2014 
(48) 
IG1&2: NA 
  
IG1:2.3¥ 
IG2: 5¥ 
 
IG1&2: NA 
 
IG1:-1.08# 
IG2: -2.48# 
P=0.003 β, P=0.28∞   
NA NA NA 
Schütz, 
2014 
(43) 
IG1&2: NA IG1: 3.4-4.25¥ 
IG2: 3.16-3.95¥ 
IG1: -8.5% ± 3.3 
IG2: -7.9% ± 3.6 
P=NA 
NA NA NA NA 
Faria 
2015 
(50) 
7 days: 
IG1: -2.6±0.2  
IG2: -2.2±0.2  
P=0.5180∞    
2 weeks: 
IG1: -3.8±0.2 Ω  
IG2: -3.0±0.2 Ω 
P=0.140∞   
7 days: NA 
2 weeks: 
IG1:-3.5 (NA) 
IG2:-2.6 (NA)  
P=NA 
7 days: NA 
2 weeks: 
IG1: -7.0±0.3  
IG2: -6.5±0.3 
P=0.3123∞   
 
 
 
NA Digital stadiometer 
 
Digital scale/ 
multifrequency 
bioimpedance 
analysis (Inbody® 
720, Biospace) 
NA 
Kalarchian 
2016 
(31) 
 
IG1: 8.3 ± 7.8§  
IG2: 3.3 ± 5.5§ 
P<0.0001∞   
IG1: 6.3% ± 5.8§ 
IG2: 2.5% ± 4.0§ 
P<0.0001∞   
IG1 & IG2:NA NA Mounted stadiometer ScaleTronix 5002 Street clothes without 
shoes 
Nielsen 
2016 
(46) 
IG1: 12·7 (SEM 0·8) 
P<0.01 from week 0 
to 7 
IG2: NA 
IG1: 9·3 (SEM 0·5) 
IG2: 13.2 (SEM 0·5) 
P=<0.01 for both from 
baseline to 7 or 14 days 
IG1&2: NA IG1:-4.2 (SEM0.8)  
IG2: NA 
P<0.01β 
Wall-mounted digital 
stadiometer 
NA Lightweight clothing, 
no shoes, emptied 
bladder and fasted 
Schouten 
2016 
(47) 
IG1: -5.9 (NA) #   
IG2: -6.0 (NA) #   
P=0.78∞  
IG1: 4.8¶ 
IG2: 4.8¶ 
IG1&2: NA IG1:-2.6 (NA) # 
IG2:-2.0 (NA) # 
P=0.43∞ 
NA “Standard scale” NA 
Baldry 
2017 
(45) 
IG1&2:NA IG1: -3.6(3.0)¥  
IG2: -3.4(3.7)¥ 
P = 0.993∞ 
IG1&2:NA NA NA NA NA 
BMI Body Mass Index, CG Control group, IG Intervention group, NA Not available. Outcome presented as mean (SD), ¥median (range) or #unclear, ^ Ideal body weight calculated as 
equivalent to a BMI of 25 kg/m2, § Preoperative phase, Ω Weight data taken from table due to discrepancies , ∞ Statistical significance between diets, β Statistical significance from pre- to post-
intervention, ¶Estimated from data provided in paper. ¥ Estimated via inference from available data. 
 
 
 
 
Table 5 Secondary outcomes following preoperative weight loss. 
Author, 
year. 
Change in liver 
volume % 
Other liver changes Surgery duration Operating difficulty Perioperative 
complications 
Changes in biochemical risk factors Changes in clinical risk factors 
Chakrava
rtty 2014 
(43) 
IG:23% 
CG:2% 
P<0.03
∞
 
(Ultrasound) 
Fibrosis. Not reported. (ARFI) IG:129min 
¥
 
CG:139min
 ¥
 
P=0.16
∞
 
 
NA “No median 
difference 
between 
groups”  
NA NA 
Heinberg 
2014 
(48) 
NA NA NA NA NA IG1&2: TG -10, +7, Chol -3.2,-0.94, LDL -
4.8,-0.72, Glu -7.63,+26.1, All not 
significant
∞
 
NA 
Schütz, 
2014 
(43) 
IG1: –471 ± 
358 ml 
IG2: –340 ± 
258 ml 
P>0.05
∞
 
(MRI) 
NA NA NA NA NA NA 
Faria 
2015 
(50) 
“No difference” 
P=0.788
∞
 
(Ultrasound) 
Steatosis at 2 weeks: 
IG1: -0.4
#
 
IG2: No change
#
 
P=0.1142
∞
  
(Ultrasound) 
“No difference” 
P=0.4455
∞
.Inverse 
relationship between 
surgery time and 
visceral fat for IG1 
P=0.0014.  
NA “No difference 
between 
groups”  
IG1&2: Glu, CRP, Chol, HDL, VLDL, TG, 
basal insulin, HOMA decreased at 14 days. 
“No statistical difference between groups & 
time”. 
 
“No difference” for BP. P=1.000∞ 
Kalarchia
n 2016 
(31) 
 
NA NA NA NA IG1: 1 patient 
reoperated 
?Reason 
NA NA 
Nielsen  
2016 
(46) 
NA NA NA NA NA Week 0-7(%): Fasting Glu -8·2 (SEM 1·8), 
insulin -28·6 (SEM 6·4), C-peptide-15·4 
(SEM 4·5, P < 0·0 β1 β. TG -9·7 (SEM 4·7), 
Chol -21·7 (SEM 2·0), LDL-23·1 (SEM 
2·2), P < 0·05
 β
. Week 7-11:No further 
decrease. 
Week 0-7: Heart rate -4·9 (SEM 
1·3) beats/min, systolic -7·1 (SEM 
2·3), diastolic BP  -7·3 (SEM 1·8) 
mmHg, all P < 0·01
 β
.Week 7-11: 
No further decrease  
 
Schouten 
2016 
(47) 
NA NA IG1: 44 mins 
IG2: 43 mins 
P=0.65 
∞
 
 
VAS score 
IG1: 31 
IG2: 36 
P=0.25
∞
 
 
IG1: 5.7% 
(n=6) 
IG2: 4.8% 
(n=5) 
P=0.76
∞
 
NA NA 
Baldry 
2017 
(45) 
NA IG1&2: “No sig difference in 
steatosis, liver injury, portal and 
lobular inflammation &fibrosis” 
(Biopsy) 
NA Increasing perceived 
difficulty associated 
with higher steatosis  
% (Biopsy) 
NA IG1&2: CRP and fetuin-A reduced 
significantly  
 
 
NA 
ARFI Acoustic Radiation Force Impulse, BP Blood pressure, Chol Total cholesterol, CG Control group, CRP C-reactive protein, GB Gastric banding, Glu Glucose, HDL High density lipoprotein, 
HOMA Homeostatic model assessment,   IG Intervention group, Lap Laparoscopic, LDL Low-density lipoprotein, NA Not available, TG Triglyceride, VAS Visual analogue score, Outcome 
presented as mean (SD), ¥median (range) or #unclear, ∞ Statistical significance between diets, β Statistical significance from pre- to post-intervention 
